Resalis Therapeutics
3 known investors
Resalis Therapeutics develops RNA-based therapies targeting non-coding RNAs to address the underlying causes of complex metabolic disorders. Its lead candidate, RES-010, is in a Phase 1 clinical trial for obesity and fatty liver disease.